INTRODUCTION
Patients with primary immunodeficiency (PID), including those with common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), are predisposed to recurrent and persistent infections [1] [2] [3] [4] [5] [6] [7] . Immunoglobulin G (IgG) replacement therapy provides an effective prophylaxis, and for 30 years, monthly intravenous immunoglobulin (IVIG) has been the standard treatment.
However, subcutaneous immunoglobulin (SCIG) given at weekly or biweekly (i.e., every 2 weeks) intervals has become an increasingly popular alternative, which has been boosted by the development of increasingly concentrated formulations (as high as 20%) enabling reduced infusion volumes and increased infusion rates [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
By comparison with monthly IVIG infusion, patients receiving a weekly SCIG dose experience similar protection and infection rates, but demonstrate increased consistency in steady-state IgG levels (reduced peak/trough variation) and suffer fewer systemic adverse events [9, 15, 16, [22] [23] [24] . In addition, SCIG preparations can be self-administered at home by most patients. This reduces treatment cost and increases patient convenience, reflected by a measured improvement in patient quality of life [25, 26] .
Subcutaneous immunoglobulin regimens typically divide the total monthly IgG dose into 4 weekly infusions. However, greater patient convenience would be achieved by increasing the flexibility of the dosing regimen and enabling individualized dosing schedules. A few clinical trials exploring alternative SCIG dosing regimens have been published [27] [28] [29] , but testing numerous regimens clinically would be time and cost intensive, and may be burdensome for patients. A powerful approach to test a broad range of dosing regimens is population pharmacokinetic (PK) modeling and simulation [30] [31] [32] [33] [34] [35] . By implementing PK models based upon existing clinical data, it is possible to simulate the kinetics of IgG following modification of variables defining a dosing regimen.
We recently developed and validated a population PK model to predict IgG concentration metrics for SCIG and IVIG dosing [36] . Model-based simulations pharmacokinetically supported that a switch from weekly SCIG to biweekly SCIG infusion at double the weekly dose maintained equivalent plasma IgG levels. The biweekly dosing regimen has recently been approved by both the US Food and Drug Administration and the European Medicines Agency for Hizentra Ò (20% SCIG;
CSL Behring AG, Bern, Switzerland) based on this modeling and simulation [37, 38] . The aim of this investigation was to use the same model to make a broader range of predictions to address the flexibility of SCIG administration. IVIG and/or Hizentra Ò SCIG, as previously described [36] . In brief, a total of 3,837 IgG concentrations from 151 unique study patients were used to develop two reference models:
RM1.5, assuming a baseline (endogenous) IgG concentration of 1.5 g/L (as expected in predominantly XLA patient populations) and RM4.0, assuming an endogenous IgG level of 4 g/ L (representative for PID population with mostly patients with CVID). The PK model is a standard two-compartment model, with SCIG absorption modeled as a first-order process (Fig. 1) . Evaluation of the reference models was performed using sensitivity analyses, visual predictive checks, and external validation [36] .
Simulations
Reference population PK models, RM4.0 and RM1. To assess poor compliance, the effect of a daily dosing regimen, in which one or two doses were skipped without replacement every week for an extended period of time, was simulated.
Loading Dose Regimens
A study consisting of 2,500 patients was simulated to measure and compare IgG concentration-time profiles for different SCIG loading dose strategies in IgG treatment-naïve patients. Six SCIG loading dose regimens were explored, as summarized in Table 1 , with 100 mg/kg/week considered as a reference dose. Following the specified loading dose, simulations proceeded with a weekly maintenance regimen.
RESULTS

Predicted Pharmacokinetic Outcomes of Varied SCIG Dosing Regimens
A broad range of SCIG dosing regimens was simulated to predict steady-state serum IgG exposures relative to a weekly SCIG regimen. While the frequency of dose administration was varied, the cumulative simulated dose remained constant (100 mg/kg/week).
Using the RM4.0 model, simulations showed that higher dosing frequency regimens provided similar IgG concentration profiles to weekly dosing, with minimal differences in either (Fig. 2) . This was reflected in the exposure metric data, where median AUC 0-7 days ratios for treatment intervals more frequent than weekly were within 3% of those for weekly administration, and C max ratios within 5%. The minimum IgG exposure was consistently greater for the more frequent dosing regimens, but not by more than 8%. This indicates that SCIG dosing regimens administered more frequently than once a week, in which the same total weekly dose is administered, would provide equivalent steadystate IgG exposures. 100 mg/kg 3 times a week 2WK 100 100 100 100 100 100 100 mg/kg 5 times a week 2WK 100 100 100 100 100 100 100 100 100 100
SCIG subcutaneous immunoglobulin a All loading dose regimens maintained with 100 mg/kg weekly SCIG from day 15 onwards With regard to regimens less frequent than weekly dosing, predicted IgG concentration profiles were similar to those for weekly and biweekly dosing, but deviations were more apparent when dosing was every 3 or 4 weeks (Fig. 2) . The average IgG exposure was consistent with frequent dosing regimens, in which median AUC ratios were within 4% of that for the weekly dose regimen, though C max and C min were notably more divergent. While median C min ratios for biweekly dosing were (Fig. 3a, b) . Exposure recovered within 2 to 3 days when administration was resumed and the next doses increased to administer the same total weekly dose (Fig. 3a) . When the skipped doses were not replaced, there was a small, but long-lasting decrease in steady-state IgG levels (Fig. 3b) On a simulated weekly dosing regimen, one, two or three skipped doses led to a decrease in average trough levels by 9, 15, and 19%, respectively. This recovered rapidly upon replacement of the skipped dose at the next infusion (Fig. 3c) . A skipped dose on a biweekly schedule led to an average decrease in trough level by 13%, which also recovered rapidly after replacement. In anticipation of a skipped dose, a double dose can be administered during a weekly or biweekly regimen. The average peak concentration after the double dose was increased by 8% on weekly, and 16% on biweekly dosing, compared with the peak concentration achieved with a standard dose.
However, the impact on subsequent trough levels was small (average 3% decrease on weekly and 5% on biweekly regimens) (Fig. 3d) .
Loading Regimens for Initiating SCIG Therapy
When SCIG therapy initiation was simulated in IgG treatment-naïve patients in the absence of a loading phase, the predicted time to achieve IgG levels of 7 g/L was 13 weeks when endogenous IgG was 4 g/L, and in excess of 24 weeks, when endogenous IgG was 1.5 g/L (Fig. 4a, b) . The respective times to achieve 90% of steady-state IgG levels were 15 weeks and 22 weeks. An intensive loading regimen of 100 mg/kg administered five times a week during the first 2 weeks of treatment (100 mg/kg 5 times a week 2WK) was predicted to rapidly achieve and were able to achieve IgG levels above 7 g/L in 2 weeks in simulations with an endogenous IgG level of 4.0 g/L (Fig. 4b) . A small transient drop in IgG level, when switching to the maintenance dose, was recovered by Week 6.
As developed models were applied to a new patient population (i.e., treatment-naïve There is also some flexibility within the dosing regimens as demonstrated by the small impact of 2-3 skipped doses on IgG levels during daily dosing, so long as the doses skipped are compensated for. These data show that if for whatever reason patients are unable to adhere strictly to their dosing regimen, it is simple and practical to compensate. For patients on a weekly or biweekly dosing regimen, trough IgG levels also recovered rapidly upon replacement of skipped doses. However, there is a greater impact on IgG trough levels when doses are skipped on these less frequent regimens, with a risk of IgG levels dropping below a protective level. It would, therefore, not be recommended to skip more than a single dose on a weekly regimen. In addition, the extra volume required to replace these doses during the following infusion could be an issue. By contrast, a double dose before a planned skipped dose had a minimal impact on the trough IgG levels for both weekly and biweekly dosing regimens.
Therefore, this would be a feasible option for patients for whom on certain occasions it may be inconvenient to maintain their usual dosing pattern. For example, patients who are traveling or on vacation may take advantage of this option.
If skipped doses are not compensated when the regular daily dosing is resumed, it takes up to 5-6 weeks to return to steady-state levels. However, in treatment-naïve patients, SCIG therapy started at a constant weekly dose may take up to 6 months to achieve steady- [7] . These patients may require a higher 'biologic IgG level'. In addition, the efficacy of Ig therapy, i.e., the dose required to achieve a given increase in IgG trough levels, varies from patient to patient, making further dose adjustment necessary [48] .
If, in a treatment-naïve patient, it can be anticipated that the target IgG trough level is higher than 7 g/L and, as a consequence, the maintenance dose is higher than 100 mg/kg/ week, a loading regimen of the planned maintenance dose administered on five consecutive days is appropriate to bring the serum IgG concentration to the target 'biologic IgG level' within one week. If, in addition, this patient has a low endogenous IgG, one and a half times the planned maintenance dose administered 5 days in Week 1 may be required.
In considering the dosing regimens assessed in our work, particularly that for loading doses, a limitation to the modeling needs to be noted.
The PK model on which the presented simulations were based was derived using data obtained in clinical trial subjects, all of whom had received IgG therapies prior to their study participation. As there was no PK data from IgG 
